Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia

International Urology and Nephrology

Volumn 32, Issue 3, 2001, Pages 423-432

  Dutkiewics, S ^a  

^a CENTRAL CLINICAL HOSPITAL   (Poland)

Author keywords

Alfuzosin; Alpha adrenoceptor; Doxazosin; Human prostate; Prazosin; Tamsulosin; Terazosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CERNITIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; FLAVONOID; PHENOXYBENZAMINE; PLACEBO; PLANT EXTRACT; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ADRENERGIC SYSTEM; ASTHENIA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; EJACULATION; FATIGUE; GYNECOMASTIA; HEADACHE; HEART PALPITATION; HUMAN; IMPOTENCE; INCIDENCE; LIBIDO; LONG TERM CARE; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SMOOTH MUSCLE RELAXATION; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT FUNCTION; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOXAZOSIN; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; QUINAZOLINES; SULFONAMIDES;

EID: 0034838423     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1017595818158     Document Type: Review

References (46)

1. New words for old: Lower urinary tract symptoms for "prostatism" - Avoid spurious suggestion of diagnostic accuracy
2. Windows of change: BPH, BPE, BPO or BOO? Be specific!
3. Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines
4. Transurethral resection for a large prostate: Is it safe?
5. Phytotherapy for the prostate
6. Long-term results of medical therapies for benign prostatic hyperplasia
7. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
8. In vitro characterization of the alpha-adrenoceptors in human prostate
9. The role of alpha blockade in the treatment of BPH
10. Benign prostatic hyperplasia. Current pharmacological treatment
11. Selective alpha-1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience
12. Utility of selective alpha-blockers (prazosin) in BPH therapy
13. Doxazosin - An alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia
14. Alpha-1-adrenergic blockers in the treatment of BPH
15. Benign prostatic hyperplasia. Current strategy and pharmacotherapeutic potential
16. Doxazosin - Alpha-1 adrenergic drug in the long-term (3 yr) management of benign prostatic hyperplasia
17. Treatment of prostatic adenoma with use of Minipress
18. 1 adrenoceptor classification; Sharpening Occam's razor
19. 1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha-1c subtype
20. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery
21. Medical therapy. BPH: A glimpse into the future
22. Prazosin concentration monitoring in the treatment of prostatic adenoma
23. Clinical assessment of the preparation Prosta-Fink in the treatment of prostatic adenoma
24. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia
25. Advances in the treatment: Alpha-1-adrenoceptor blockers for patients with BPH
26. Doxazosin - An alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH)
27. A comparative study of long-term alpha-1 blocker doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia
28. Long-term (5 yr) efficacy of doxazosin in the treatment for BPH. Abstract, XVII Congress of the Polish Association of Urologists (June, 12-14, 1997)
29. Doxazosin is equally well tolerated by older and younger normotensive men
30. Long-term efficacy and safety of doxazosin for the treatment of benign prostatic hyperplasia
31. Doxazosin in hypertension. Results of a general practice study in 4809 patients
32. Alfuzosin for treatment of benign prostatic hyperplasia
33. Benign prostatic hyperplasia: Outcome of long term treatment with an alpha-blocker
34. Efficacy and safety of sustained realse alfuzosin 5 mg in patients with benign prostatic hyperplasia
35. Placebo controlled study of benign prostatic hyperplasia with a 2-year follow up
36. Terazosin and doxazosin in normotensive men with symptomatic prostatism. A pilot study to determine the effect of dosing regimen on efficacy and safety
37. Use of recombinant alpha-1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy
38. Tamsulosin, the first prostate-selective alpha-1A-adrenoceptor antagonist
39. Tamsulosin, the first prostate-selective alpha-1A-adrenoceptor antagonist
40. The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,772 patients
41. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia
42. Assessment of the safety and efficacy of terazosin and finasteride in patients with symptomatic BPH
43. Doxazosin/finasteride combination therapy after 3 years doxazosin monotherapy. Evaluation of treatment for BPH
44. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia. A randomised international study of 1098 patients